Navigation Links
Data from Rexahn Pharmaceuticals' Phase I Trial of RX-0201,(Archexin) to Be Presented at the 43rd American Society of Clinical,Oncology Annual Meeting in Chicago

ROCKVILLE, Md.--(BUSINESS WIRE)--May 30, 2007 - Rexahn Pharmaceuticals, Inc. (OTC BB:RXHN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, today announced that Dr. John Marshall, Principal Investigator of Phase I clinical trial of the Company's lead cancer compound RX-0201 (Archexin), will present results of the clinical study at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1-5, 2007 at McCormick Place in Chicago, Illinois.

The presentation, entitled, "A Phase I Trial of RX-0201 (AKT anti-sense) in Patients with Advanced Cancer," is scheduled for Sunday, June 3, 2007 at 9am Central Time.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a biopharmaceutical company leveraging its unique technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. For Additional information about Rexahn visit


Rexahn Pharmaceuticals, Inc.
Amanda Sawney, 240-268-5300 x300


Page: 1

Related medicine technology :

1. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
2. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:10/12/2015)... YORK , Oct. 12, 2015 About ... Epilepsy refers to a spectrum of brain disorders manifested ... is caused by factors ranging from brain malformations and ... When the underlying cause of the disease is unidentified, ... is known as idiopathic epilepsy. An imbalance between the ...
(Date:10/12/2015)... 2015 --> --> ... by Product (Hand-held, Table-top, Desktop), Technology (Volume Measurement, Flow Measurement, ... - Global Forecast to 2020", published by MarketsandMarkets, the Spirometer ... at a CAGR of 9.8% from 2015 to 2020. ... igures spread th rough 187 P ages and ...
(Date:10/12/2015)... IRVINE, Calif. , Oct. 12, 2015  Edwards Lifesciences ... science of heart valves and hemodynamic monitoring, plans to announce ... after the market closes on Monday, October 26, 2015, and ... day to discuss those results. . A ... mobile devices by downloading Edwards, IR App for iPhone ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Doulagivers is O'Brien's licensed ... and End of Life Doula Training. A Doulagiver is a non-medical person ... emotionally. Based on her #1 International bestselling book Creating Positive Passings & ...
(Date:10/12/2015)... SOUTH BELOIT, IL (PRWEB) , ... October 13, 2015 , ... ... Industrial Buyers Consortium (IBC) at the 2015 IBC National Meeting in Rosemont, IL on ... best represent the dedication, quality, and standards of excellence that customers have come to ...
(Date:10/12/2015)... ... October 12, 2015 , ... According to an article ... athletes, particularly in the area of track and field, are at a significantly ... male peers in the same age group. Dr. Steven Meier of Meier Orthopedic ...
(Date:10/12/2015)... Illinois (PRWEB) , ... October 12, 2015 , ... ... support the practice of hypnosis by individuals who lack professional education and clinical ... hypnosis to the public for a variety of purposes such as: losing weight, ...
(Date:10/12/2015)... ... October 12, 2015 , ... The Horizon Foundation for New Jersey has awarded ... health and enhancing the quality of life in the Garden State. The grants, representing ... organizations. , The charitable arm of Horizon Blue Cross Blue Shield of New ...
Breaking Medicine News(10 mins):